Mplx (NYSE:MPLX) Announces Earnings Results, Beats Expectations By $0.02 EPS
- On Tuesday, November 3, 2026, Fortis Inc. released third-quarter results and introduced a new $32.2 billion five-year capital plan while increasing its fourth-quarter dividend by 4%.
- The company reported third-quarter net earnings of $474 million, or $0.92 per common share, up from $409 million, or $0.81 per share, in the same quarter of 2025.
- Fortis' new $32.2 billion capital plan, $3.4 billion higher than the previous forecast, emphasizes transmission investments at ITC and expanded liquefied natural gas storage at FortisBC Energy.
- ITC won a competitive $1.0 billion Iowa transmission project, with $0.5 billion included in the five-year plan; an Arizona Corporation Commission Administrative Law Judge issued a recommended rate order for Tucson Electric Power .
- Fortis extended annual dividend growth guidance of 4-6% through 2031, supported by regulated investment opportunities and long-term rate base expansion projected to reach $63.9 billion by 2031.
28 Articles
28 Articles
4 Companies Just Raised Their Dividends. Which Payout Has the Most Room to Grow?
Visa, Entergy, Tennant, and Fortis all just lifted their quarterly payouts, but a dividend raise is only as good as the cash flow standing behind it. One of these four companies raised its payout while its earnings coverage was already running thin.
Mplx (NYSE:MPLX) Announces Earnings Results, Beats Expectations By $0.02 EPS
Mplx (NYSE:MPLX - Get Free Report) issued its quarterly earnings results on Tuesday. The pipeline company reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.02. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.35 billion. Mplx had a net margin of 35.75% and a return on equity of 32.83%.
Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?
Key PointsPfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts.The company experienced 32% growth from launched and acquired products, highlighting its underrated growth potential.Its valuation remains modest, despite the stock's strong gains this year.Motley Fool Issues Rare "Total Conviction" Buy Alert › On Tuesday, healthcare giant Pfizer (NYSE:PFE) reported its th…
Coverage Details
Bias Distribution
- 41% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
